Joseph M. Connors, MD: Optimizing Therapy, Minimizing Toxicity in Hodgkin Lymphoma
325 views · Published 18 September 2016 · 6:56 · Indexed 20 September 2026
Channel: American Society of Hematology · 2016 · Nonprofits & Activism
With improved diagnostics and new therapies, patients with Hodgkin lymphoma have experienced long-term cure rates, but there is still a need to minimize long-term toxicities. Joseph M. Connors, MD, discusses optimizing therapy for these patients.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
3:56
ASH and the Reagans Support Stem Cell Research
-
6:35
ASH News TV: Late Breaking Abstracts & ASH SAP 5th Addition
-
2:34
ASH State-of-the-Art Symposium
-
3:42
CLL-IPI: A New and Improved Staging System for CLL?
-
4:44
About the ASH Clinical Research Training Institute
-
1:30
2017 ASH MHM: Focus on Leukemia – Anjali Advani, MD
-
1:30
Meet the Co-Chairs: 2018 ASH Meeting on Lymphoma Biology